What's New


Chau Hoi Shuen Foundation continues to support “Dear Girlfriends” for relieving financial burden of female patients for sophisticated cancer treatment

(21 September 2022, Hong Kong) HKSH Medical Group (HKSH) today announced the generous donation of HK$10 million from Chau Hoi Shuen Foundation (CHSF) for another year to support female patients with financial needs for more precise and high-end cancer treatment at HKSH.
Since July 2019, Chau Hoi Shuen Foundation has started to subsidise patients with financial difficulties to receive cancer treatment at HKSH.
Phase 1
July 2019 – December 2020 
Donation: HK$10 million
Number of subsidised patient: 78
The scheme covers breast cancer, liver and biliary tract cancer, lung cancer, bowel cancer, nasopharyngeal cancer, pancreatic cancer, and cervical cancer, etc.
Phase 2
January 2021 – July 2022
Donation: HK$15 million
Number of subsidised patient: 144 

(46% of the beneficiaries with a monthly household income of less than HK$30,000)  
The scheme covers breast cancer, pancreatic cancer, cervical cancer, intracranial malignant tumor and gynecological related cancers. 
Phase 3
September 2022 onwards
Donation: HK$10 million
Estimated number of subsidised female patient: 106  
The scheme covers breast cancer with regional nodal disease, gynecological related cancers, and cervical cancer. 
In January 2021, CHSF named the subsidy scheme for cancer treatment as “Dear Girlfriends”. Together with the newly announced donation, CHSF has donated a cumulative total of HK$35 million.
With the aim of supporting more female cancer patients in need, the new round of “Dear Girlfriends” project commenced in September 2022 and is expected to benefit around 106 patients. Under the scheme, eligible patients must be referred by HKSH or the Li Ka Shing Faculty of Medicine of The University of Hong Kong. Each beneficiary can receive a subvention of up to HK$260,000, subject to the type of treatment they need. The Scheme covers three treatment plans as listed in the below.
(1)    Helical Tomotherapy for Breast Cancer Patients with Regional Nodal Disease
(2)    MR-guided Radiotherapy using MR Linac for Gynaecological Cancer Patients
(3)    MR-guided Brachytherapy for Cervix Cancer Patients
Please click here for more information.